Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of PIT565 in relapsed or refractory B-cell malignancies
jRCT2031220330Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of PIT565 in mature B-cell lymphoma and acute lymphoblastic leukemia (ALL) (5 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose-limiting toxicities, Adverse events and serious adverse events and 2 more. Started May 2023; status: active, not recruiting.
02
Drugs
PIT565
03
Conditions
mature B-cell lymphomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031220330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220330.